Synagis (generic: palivizumab) is a prescription medication used to help prevent a serious lung disease caused by Respiratory Syncytial Virus (RSV) in children younger than 24 months of age (at the start of dosing). Synagis belongs to a group of drugs called monoclonal antibodies which work by preventing the virus from replicating.

This medication comes in an injectable form to be given once a month for several months.

Common side effects of Synagis include fever, rash, and redness or swelling at the injection site.